JPS5843926A
(ja)
*
|
1981-09-08 |
1983-03-14 |
Suntory Ltd |
選択性制癌剤
|
FR2523445A1
(fr)
*
|
1982-03-17 |
1983-09-23 |
Sanofi Sa |
Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
|
DE3369466D1
(en)
*
|
1982-05-12 |
1987-03-05 |
Harvard College |
Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
|
US4520226A
(en)
*
|
1982-07-19 |
1985-05-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
|
JPS5990052A
(ja)
*
|
1982-11-16 |
1984-05-24 |
Katsu Taniguchi |
モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
|
US4916213A
(en)
*
|
1983-02-22 |
1990-04-10 |
Xoma Corporation |
Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
|
US4591572A
(en)
*
|
1983-04-01 |
1986-05-27 |
Sloan-Kettering Institute For Cancer Research |
Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
|
JPS59186924A
(ja)
*
|
1983-04-08 |
1984-10-23 |
Kureha Chem Ind Co Ltd |
ヒト免疫グロブリン結合抗腫瘍剤
|
US4664911A
(en)
*
|
1983-06-21 |
1987-05-12 |
Board Of Regents, University Of Texas System |
Immunotoxin conjugates employing toxin B chain moieties
|
GB2142428A
(en)
*
|
1983-06-23 |
1985-01-16 |
Erba Farmitalia |
Adenocarcinoma related antigenic determinants and antibodies specific thereto
|
FR2547731A1
(fr)
*
|
1983-06-27 |
1984-12-28 |
Centre Nat Rech Scient |
Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
|
GB2148299B
(en)
*
|
1983-09-01 |
1988-01-06 |
Hybritech Inc |
Antibody compositions of therapeutic agents having an extended serum half-life
|
US4545985A
(en)
*
|
1984-01-26 |
1985-10-08 |
The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services |
Pseudomonas exotoxin conjugate immunotoxins
|
FR2570278B1
(fr)
*
|
1984-09-14 |
1987-02-13 |
Pasteur Institut |
Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
|
AU585940B2
(en)
*
|
1984-09-25 |
1989-06-29 |
Xoma Corporation |
Lectin immunotoxins
|
US4590071A
(en)
*
|
1984-09-25 |
1986-05-20 |
Xoma Corporation |
Human melanoma specific immunotoxins
|
EP0232447A1
(en)
*
|
1986-02-13 |
1987-08-19 |
Xoma Corporation |
Lectin immunotoxins
|
FR2573656B1
(fr)
*
|
1984-11-29 |
1987-02-27 |
Sanofi Sa |
Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
|
US4851510A
(en)
*
|
1984-11-30 |
1989-07-25 |
Wadley Technologies, Inc. |
Monoclonal antibodies to novel melanoma-associated antigens
|
AT384549B
(de)
*
|
1985-01-08 |
1987-11-25 |
Strasser Engelbert |
Verfahren zur herstellung einer vaccine
|
US5256413A
(en)
*
|
1985-01-08 |
1993-10-26 |
The General Hospital Corporation |
Method and use for site-specific activation of substances
|
FR2577135B1
(fr)
*
|
1985-02-13 |
1989-12-15 |
Sanofi Sa |
Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
|
US4744981A
(en)
*
|
1985-10-17 |
1988-05-17 |
Neorx Corporation |
Trichothecene antibody conjugates
|
DE3688137D1
(de)
*
|
1985-11-29 |
1993-04-29 |
Consolidated Pharmaceuticals L |
Ricin-antikoerper-konjugate.
|
US4831122A
(en)
*
|
1986-01-09 |
1989-05-16 |
Regents Of The University Of Minnesota |
Radioimmunotoxins
|
US4689401A
(en)
*
|
1986-03-06 |
1987-08-25 |
Cetus Corporation |
Method of recovering microbially produced recombinant ricin toxin a chain
|
USRE38008E1
(en)
|
1986-10-09 |
2003-02-25 |
Neorx Corporation |
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
US4771128A
(en)
*
|
1986-10-10 |
1988-09-13 |
Cetus Corporation |
Method of purifying toxin conjugates using hydrophobic interaction chromatography
|
US5009995A
(en)
*
|
1986-10-27 |
1991-04-23 |
Sloan-Kettering Institute For Cancer Research |
Monoclonal antibodies to melanoma cells
|
US5372812A
(en)
*
|
1988-04-04 |
1994-12-13 |
The General Hospital Corporation |
Composition and method for acceleration of clot lysis
|
US5582862A
(en)
*
|
1988-04-04 |
1996-12-10 |
General Hospital Corporation |
Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
|
US5609869A
(en)
*
|
1988-08-19 |
1997-03-11 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5811265A
(en)
*
|
1988-08-19 |
1998-09-22 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5252713A
(en)
*
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
US5171563A
(en)
*
|
1988-09-30 |
1992-12-15 |
Neorx Corporation |
Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
|
IE910820A1
(en)
*
|
1990-03-22 |
1991-09-25 |
Sloan Kettering Inst Cancer |
Gp75 as a tumor vaccine for melanoma
|
IL97776A
(en)
*
|
1990-04-19 |
2000-10-31 |
Res Dev Foundation |
Composition comprising a conjugate of a ZME antibody and a biological response modifier
|
US5981194A
(en)
*
|
1992-07-10 |
1999-11-09 |
University Of British Columbia |
Use of p97 and iron binding proteins as diagnostic and therapeutic agents
|
US5690935A
(en)
*
|
1995-01-13 |
1997-11-25 |
Regents Of The University Of Minnesota |
Biotherapy of cancer by targeting TP-3/P80
|
AU6113396A
(en)
|
1995-06-14 |
1997-01-15 |
Regents Of The University Of California, The |
Novel high affinity human antibodies to tumor antigens
|
CA2266341A1
(en)
*
|
1996-09-20 |
1998-03-26 |
The General Hospital Corporation |
Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
|
US6869604B1
(en)
*
|
1998-03-27 |
2005-03-22 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant anti-tumor RNAse
|
ES2322723T5
(es)
*
|
1998-05-08 |
2013-03-11 |
The Regents Of The University Of California |
Métodos para detectar e inhibir la angiogénesis
|
US6852318B1
(en)
|
1998-05-08 |
2005-02-08 |
The Regents Of The University Of California |
Methods for detecting and inhibiting angiogenesis
|
CA2424817A1
(en)
|
2000-10-06 |
2002-04-11 |
Quantum Dot Corporation |
Cells having a spectral signature, and methods of preparation and use thereof
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
US7378280B2
(en)
|
2000-11-16 |
2008-05-27 |
California Institute Of Technology |
Apparatus and methods for conducting assays and high throughput screening
|
ZA200305980B
(en)
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
WO2002100172A1
(en)
*
|
2001-06-11 |
2002-12-19 |
Xenoport, Inc. |
Administration of agents via the pept-2 transporter
|
JP2004535202A
(ja)
*
|
2001-07-17 |
2004-11-25 |
リサーチ ディベロップメント ファンデーション |
アポトーシス促進性蛋白質を含む治療剤
|
ES2403560T3
(es)
|
2001-11-30 |
2013-05-20 |
Fluidigm Corporation |
Dispositivo microfluídico y procedimientos de utilización del mismo
|
US20030158089A1
(en)
*
|
2002-01-24 |
2003-08-21 |
Xenoport, Inc. |
Administrative agents via the SMVT transporter
|
US20030158254A1
(en)
*
|
2002-01-24 |
2003-08-21 |
Xenoport, Inc. |
Engineering absorption of therapeutic compounds via colonic transporters
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US20030228619A1
(en)
*
|
2002-06-10 |
2003-12-11 |
Xenoport, Inc. |
Peptide nucleic acids as tags in encoded libraries
|
EP1572170A4
(en)
*
|
2002-06-12 |
2007-02-28 |
Res Dev Foundation |
IMMUNOTOXIN AS THERAPEUTIC AGENT AND USES THEREOF
|
TR200500108T2
(tr)
|
2002-07-18 |
2005-04-21 |
Helix Biopharma Corp. |
Kanser Hücresi Gelişiminin İnhibe Edilmesinde Üreaz Kullanımı
|
US20040161424A1
(en)
*
|
2002-10-08 |
2004-08-19 |
Xenoport |
Human organic solute transporters
|
US7666361B2
(en)
|
2003-04-03 |
2010-02-23 |
Fluidigm Corporation |
Microfluidic devices and methods of using same
|
CA2553040A1
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
CN102603895B
(zh)
|
2004-06-18 |
2016-09-28 |
Ambrx公司 |
新颖抗原结合多肽和其用途
|
BRPI0512396A
(pt)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
WO2006053380A1
(en)
*
|
2004-11-16 |
2006-05-26 |
Sienna Cancer Diagnostics Ltd |
Methods of detecting an analyte in a sample
|
WO2006073846A2
(en)
|
2004-12-22 |
2006-07-13 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
US7385028B2
(en)
|
2004-12-22 |
2008-06-10 |
Ambrx, Inc |
Derivatization of non-natural amino acids and polypeptides
|
KR101252835B1
(ko)
|
2004-12-22 |
2013-04-10 |
암브룩스, 인코포레이티드 |
아미노아실-tRNA 합성효소의 조성물 및 그것의 용도
|
NZ555386A
(en)
|
2004-12-22 |
2011-01-28 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
KR20070090023A
(ko)
|
2004-12-22 |
2007-09-04 |
암브룩스, 인코포레이티드 |
변형 인간 성장 호르몬
|
EP1855724A2
(en)
*
|
2005-02-01 |
2007-11-21 |
Research Development Foundation |
Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
|
EP2518161A1
(en)
|
2005-03-18 |
2012-10-31 |
Fluidigm Corporation |
Method for detection of mutant alleles
|
CN101247821B
(zh)
*
|
2005-06-03 |
2013-01-23 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
KR101285904B1
(ko)
*
|
2005-08-18 |
2013-07-15 |
암브룩스, 인코포레이티드 |
tRNA 조성물 및 이의 용도
|
PL1954710T3
(pl)
*
|
2005-11-08 |
2011-09-30 |
Ambrx Inc |
Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie
|
KR20080079643A
(ko)
*
|
2005-11-16 |
2008-09-01 |
암브룩스, 인코포레이티드 |
비-천연 아미노산을 포함하는 방법 및 조성물
|
US20080317670A1
(en)
*
|
2005-12-14 |
2008-12-25 |
Ambrx, Inc. |
Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
|
KR20090051227A
(ko)
*
|
2006-09-08 |
2009-05-21 |
암브룩스, 인코포레이티드 |
척추동물 세포를 위한 하이브리드 서프레서 tRNA
|
PT2064333E
(pt)
*
|
2006-09-08 |
2014-06-09 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
EP2069396B1
(en)
*
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
US8354110B2
(en)
|
2007-03-07 |
2013-01-15 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of autoimmune conditions
|
CN104163864B
(zh)
*
|
2007-03-30 |
2017-08-01 |
Ambrx公司 |
经修饰fgf‑21多肽和其用途
|
AU2008247815B2
(en)
*
|
2007-05-02 |
2012-09-06 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CA2699394C
(en)
|
2007-09-17 |
2020-03-24 |
The Regents Of The University Of California |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
CN108129573B
(zh)
|
2007-09-21 |
2021-10-08 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
MX338336B
(es)
*
|
2007-11-20 |
2016-04-07 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
IL198123A0
(en)
|
2008-04-18 |
2009-12-24 |
Snecma Propulsion Solide |
A heat treatment oven with inductive heating
|
EP2304439A4
(en)
|
2008-05-29 |
2012-07-04 |
Nuclea Biotechnologies Llc |
ANTI-phospho-AKT ANTIBODY
|
PT2318029T
(pt)
*
|
2008-07-23 |
2018-01-10 |
Ambrx Inc |
Polipéptidos de g-csf bovino modificados e suas utilizações
|
EP2342223B1
(en)
|
2008-09-26 |
2017-04-26 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
ES2660000T3
(es)
*
|
2008-09-26 |
2018-03-20 |
Ambrx, Inc. |
Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
|
ES2626327T3
(es)
|
2009-02-06 |
2017-07-24 |
The Regents Of The University Of California |
Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas
|
US20120283171A1
(en)
|
2009-12-21 |
2012-11-08 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
SG181769A1
(en)
|
2009-12-21 |
2012-07-30 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
WO2011133948A2
(en)
|
2010-04-22 |
2011-10-27 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
PL2605789T3
(pl)
|
2010-08-17 |
2019-11-29 |
Ambrx Inc |
Zmodyfikowane polipeptydy relaksyny i ich zastosowania
|
JP6133208B2
(ja)
|
2010-09-15 |
2017-05-24 |
マースニー, ランドル, ジェイMRSNY, Randall, J |
細菌毒素由来輸送配列を使用する生物活性剤の送達の系および方法
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
KR101972291B1
(ko)
|
2010-09-29 |
2019-08-16 |
유티아이 리미티드 파트너쉽 |
생체적합성, 생흡수성 나노구를 사용하는 자가면역 질병의 치료방법
|
US9511151B2
(en)
|
2010-11-12 |
2016-12-06 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of cancer
|
EP2684048B1
(en)
|
2011-03-11 |
2018-10-03 |
Board of Regents of the University of Nebraska |
Biomarker for coronary artery disease
|
EP2694095B1
(en)
|
2011-04-05 |
2018-03-07 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
CA2837167A1
(en)
|
2011-05-27 |
2012-12-06 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
|
CN110078787A
(zh)
|
2011-05-27 |
2019-08-02 |
Ambrx 公司 |
含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
|
HUE049945T2
(hu)
|
2012-03-03 |
2020-11-30 |
Immungene Inc |
Módosított antitest-interferon mutáns fúziós molekulák
|
US10988516B2
(en)
|
2012-03-26 |
2021-04-27 |
Uti Limited Partnership |
Methods and compositions for treating inflammation
|
EP3536700A1
(en)
|
2012-06-07 |
2019-09-11 |
Ambrx, Inc. |
Prostate-specific membrane antigen antibody drug conjugates
|
MX2014015205A
(es)
|
2012-06-14 |
2015-08-14 |
Ambrx Inc |
Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
|
AU2013277169B2
(en)
|
2012-06-19 |
2017-02-02 |
Ambrx, Inc. |
Anti-CD70 antibody drug conjugates
|
US9603948B2
(en)
|
2012-10-11 |
2017-03-28 |
Uti Limited Partnership |
Methods and compositions for treating multiple sclerosis and related disorders
|
WO2014145718A2
(en)
|
2013-03-15 |
2014-09-18 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
US11559580B1
(en)
|
2013-09-17 |
2023-01-24 |
Blaze Bioscience, Inc. |
Tissue-homing peptide conjugates and methods of use thereof
|
US10519247B2
(en)
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
EP3065771B1
(en)
|
2013-11-04 |
2019-03-20 |
UTI Limited Partnership |
Methods and compositions for sustained immunotherapy
|
FR3018526B1
(fr)
|
2014-03-14 |
2021-06-11 |
Herakles |
Installation de densification cvi comprenant une zone de prechauffage a forte capacite
|
CA2948346C
(en)
|
2014-05-07 |
2023-06-27 |
Applied Molecular Transport Llc |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
KR20240024362A
(ko)
|
2014-10-24 |
2024-02-23 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
US12011480B2
(en)
|
2015-05-06 |
2024-06-18 |
Uti Limited Partnership |
Nanoparticle compositions for sustained therapy
|
SG10201913746RA
(en)
|
2015-11-03 |
2020-03-30 |
Ambrx Inc |
Anti-cd3-folate conjugates and their uses
|
PT3383920T
(pt)
|
2015-11-30 |
2024-04-15 |
Univ California |
Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
|
US20190161523A1
(en)
|
2016-04-12 |
2019-05-30 |
Blaze Bioscience, Inc. |
Methods of treatment using chlorotoxin conjugates
|
WO2017181149A1
(en)
|
2016-04-15 |
2017-10-19 |
Blaze Bioscience, Inc. |
Methods of treating breast cancer
|
US12049511B2
(en)
|
2016-11-10 |
2024-07-30 |
Fortis Therapeutics, Inc. |
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
|
US11434301B2
(en)
|
2016-11-11 |
2022-09-06 |
The Regents Of The University Of California |
Anti-CD46 antibodies and methods of use
|
JP2020503857A
(ja)
|
2016-12-12 |
2020-02-06 |
セファイド |
自動反応カートリッジにおける統合化イムノpcr及び核酸分析
|
CN110300595A
(zh)
|
2017-01-05 |
2019-10-01 |
加利福尼亚大学董事会 |
Pac1受体激动剂(maxcap)及其用途
|
SG10201912034UA
(en)
|
2017-02-08 |
2020-02-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
PT3762009T
(pt)
|
2018-03-08 |
2022-08-22 |
Applied Molecular Transport Inc |
Construções de administração derivadas de toxinas para administração oral
|
SG11202009925PA
(en)
|
2018-03-08 |
2020-11-27 |
Applied Molecular Transport Inc |
Toxin-derived delivery constructs for oral delivery
|
FI3773910T3
(fi)
|
2018-03-29 |
2024-08-29 |
Ambrx Inc |
Humanisoituja eturauhasspesifisen membraaniantigeeni (psma) -vasta-aineen ja lääkkeen konjugaatteja
|
BR112021003843A2
(pt)
|
2018-08-28 |
2021-05-25 |
Ambrx, Inc. |
biconjugados de folato de anticorpo anti-cd3 e seus usos
|
CA3111576A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
KR20210136014A
(ko)
|
2019-02-12 |
2021-11-16 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
|
WO2021034727A1
(en)
|
2019-08-16 |
2021-02-25 |
Applied Molecular Transport Inc. |
Compositions, formulations, and interleukin production and purification
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
AU2021320333A1
(en)
|
2020-08-07 |
2023-03-30 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting CD46 and methods of use thereof
|
JP2023538071A
(ja)
|
2020-08-20 |
2023-09-06 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲート、その方法及び使用
|
EP4313163A1
(en)
|
2021-04-03 |
2024-02-07 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2024077277A1
(en)
|
2022-10-07 |
2024-04-11 |
Ambrx, Inc. |
Drug linkers and antibody conjugates thereof
|
WO2024155627A1
(en)
|
2023-01-16 |
2024-07-25 |
Ambrx, Inc. |
Anti-cd70 antibody-drug conjugates
|
WO2024178310A1
(en)
|
2023-02-23 |
2024-08-29 |
Ambrx, Inc. |
Trop2-directed antibody-drug conjugates and uses thereof
|